علاج الذئبة الحمامية القرصية مع آفات جلدية شديدة أو منتشرة

References

1. We recommend antimalarials as first-line and long-term systemic treatment in all CLE patients with severe or widespread skin lesions, in particular in patients with the risk of scarring and development of systemic disease.
2. In severe or widespread active CLE lesions, systemic corticosteroids are recommended as first-line treatment in addition to antimalarials.
3. We recommend retinoids as second-line systemic treatment in selected CLE patients unresponsive to other treatments, preferably in addition to antimalarials.
4. In CLE, the recommended dose for acitretin and isotretinoin is 0.2 to 1.0 mg/kg body weight/day.
5. We recommend dapsone as second-line treatment in refractory CLE, preferably in addition to antimalarials.
6. We recommend to start dapsone with a low dose treatment (50 mg/day) and to increase it to a maximum of 1.5 mg/kg according to clinical response and side-effects.
7. The response to retinoid therapy usually is rapid, occurring within the first 2 to 6 weeks of treatment.